The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...